Zimmer Biomet Holdings (ZBH) has had a busy phase, dominated by significant acquisitions and increases in stock positions by several asset managers. The company's strategic move to purchase
Monogram Technologies has been well-received and is expected to bolster their robotics portfolio significantly. Their merger with Monogram and the successful acquisition of Paragon 28 underlines this focus. Zimmer Biomet has also ventured into niche areas with the unveiling of
two novel foot and ankle trauma solutions and the launch of the world's first iodine-treated total hip replacement system, following approval in Japan. Financially, Zimmer Biomet announced promising quarterly financial results for Q2 and Q3 of 2025, along with an increase in the annual profit forecast. In parallel, there has been notable activity with shares of Zimmer Biomet, with ownership changes at
Callan Family Office LLC, Truist Financial Corp, Costello Asset Management INC, Janney Montgomery Scott LLC among several other entities. Despite Zimmer's shares experiencing some turbulence, the company's underlying earnings have shown growth. With a recently reconfirmed hold rating, and an upward adjustment of their 2025 EPS view, Zimmer Biomet is expected to continue a positive trajectory.
Zimmer Biomet Holdings ZBH News Analytics from Tue, 28 Jan 2025 08:00:00 GMT to Sat, 11 Oct 2025 12:31:21 GMT -
Rating 5
- Innovation 2
- Information 6
- Rumor -5
